Effect of treatment with sitagliptin on somatosensory-evoked potentials and metabolic control in patients with type 2 diabetes mellitus.

Arquivos brasileiros de endocrinologia e metabologia Pub Date : 2014-06-01 DOI:10.1590/0004-2730000002914

Joelma Ines Tagliapietra Barros, Francisco Vagnaldo Fechine, Renan Magalhães Montenegro Júnior, Otoni Cardoso do Vale, Virgínia Oliveira Fernandes, Marcellus Henrique Loiola Ponte de Souza, Gilmara Holanda da Cunha, Manoel Odorico de Moraes, Catarina Brasil d'Alva, Maria Elisabete Amaral de Moraes

{"title":"Effect of treatment with sitagliptin on somatosensory-evoked potentials and metabolic control in patients with type 2 diabetes mellitus.","authors":"Joelma Ines Tagliapietra Barros, Francisco Vagnaldo Fechine, Renan Magalhães Montenegro Júnior, Otoni Cardoso do Vale, Virgínia Oliveira Fernandes, Marcellus Henrique Loiola Ponte de Souza, Gilmara Holanda da Cunha, Manoel Odorico de Moraes, Catarina Brasil d'Alva, Maria Elisabete Amaral de Moraes","doi":"10.1590/0004-2730000002914","DOIUrl":null,"url":null,"abstract":"Objective: To evaluate the effect of sitagliptin on somatosensory-evoked potentials (SEPs) and metabolic control in patients with type 2 diabetes mellitus without clinical diabetic neuropathy.Materials and methods: Interventional, prospective, and open study. Patients with less than six months from the diagnosis were included. Examinations of SEPs and laboratory tests at fasting and after food stimulation were performed before and after three months of treatment with sitagliptin (100 mg/day).Results: There was a reduction in the mean levels of HbA1c (P < 0.0001), fasting glucose (P = 0.001), total cholesterol (P = 0.019), and ALT (P = 0.022). An increase in active GLP-1 was found at the end of the study (P = 0.0025). Several SEPs showed statistically significant differences when analyzed before and after treatment with sitagliptin.Conclusion: The results give a glimpse of the possible use of sitagliptin in the treatment of some neurodegenerative conditions of the peripheral nervous system, in addition to its already established role in glycemic control.","PeriodicalId":8395,"journal":{"name":"Arquivos brasileiros de endocrinologia e metabologia","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2014-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1590/0004-2730000002914","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Arquivos brasileiros de endocrinologia e metabologia","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1590/0004-2730000002914","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 2

Abstract

Objective: To evaluate the effect of sitagliptin on somatosensory-evoked potentials (SEPs) and metabolic control in patients with type 2 diabetes mellitus without clinical diabetic neuropathy.

Materials and methods: Interventional, prospective, and open study. Patients with less than six months from the diagnosis were included. Examinations of SEPs and laboratory tests at fasting and after food stimulation were performed before and after three months of treatment with sitagliptin (100 mg/day).

Results: There was a reduction in the mean levels of HbA1c (P < 0.0001), fasting glucose (P = 0.001), total cholesterol (P = 0.019), and ALT (P = 0.022). An increase in active GLP-1 was found at the end of the study (P = 0.0025). Several SEPs showed statistically significant differences when analyzed before and after treatment with sitagliptin.

Conclusion: The results give a glimpse of the possible use of sitagliptin in the treatment of some neurodegenerative conditions of the peripheral nervous system, in addition to its already established role in glycemic control.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

西格列汀治疗对2型糖尿病患者躯体感觉诱发电位及代谢控制的影响。

目的:探讨西格列汀对无临床糖尿病神经病变的2型糖尿病患者躯体感觉诱发电位(SEPs)及代谢控制的影响。材料和方法:介入性、前瞻性和开放性研究。诊断后不到6个月的患者被纳入研究。在西格列汀(100mg /天)治疗3个月之前和之后分别进行空腹和食物刺激时的sep检查和实验室检查。结果:HbA1c (P < 0.0001)、空腹血糖(P = 0.001)、总胆固醇(P = 0.019)和ALT (P = 0.022)的平均水平均有降低。研究结束时发现活性GLP-1增加(P = 0.0025)。在西格列汀治疗前后分析几项sep差异有统计学意义。结论:这些结果为西格列汀在治疗周围神经系统的一些神经退行性疾病提供了可能的一瞥，除了它已经确定的血糖控制作用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊